RxDoctor Payments Data

James Scott, MD

Surgery · Saint Louis, MONPI 1134115637

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (44.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 98.7% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2021 at $87,555 and has fallen 92.2% since, to $6,809 in 2025. Among surgery clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$307,019in general payments, 2019–2025

Across 369 payments — averaging $832.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$303K
  • Johnson & Johnson$2K
  • Endogastric Solutions, Inc$1K
  • AbbVie$298
  • TELA Bio, Inc.$127
  • Covidien LP$112
  • plus $662 from 22 others

What the payments were for

  • Consulting fees$24,5758%
  • Speaking & faculty fees$110,25036%
  • Travel & lodging$28,8269%
  • Food & beverage$7,6702%
  • Education$135,50044%
  • Gifts$1990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$307,019 in reported general payments places this provider in the 95th percentile of 612 surgery providers in Missouri.

See all surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$190,231
Medicare patients
175
Services billed
715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide13$580,012
CreonLipase/Protease/Amylase65$50,689
LinzessLinaclotide45$30,111
Ondansetron OdtOndansetron66$1,661
Sucralfate32$1,365
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,231
Pantoprazole Sodium60$963
Omeprazole76$860
Colestipol Hcl14$794
Clindamycin Hcl55$431
Clotrimazole43$404
Gabapentin28$298
Acarbose11$289
Amitriptyline Hcl21$69
Potassium Chloride13$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$58$580,01213 claims
AbbVieCreon, Linzess$298$80,799110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 612 surgery providers in Missouri.

Other surgery in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →